Ocugen Falls as Gene Therapy for Eye Disease Lags in Phase II StudyZacks Investment Research • 03/25/26
Ocugen, Inc. (OCGN) Discusses Top Line Results From Phase II ArMaDa Trial of OCU410 in Geographic Atrophy TranscriptSeeking Alpha • 03/24/26
Ocugen Announces Topline 12-month Data from Phase 2 ArMaDa Clinical Trial Evaluating OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular DegenerationGlobeNewsWire • 03/24/26
Ocugen to Host Webcast on Tuesday, March 24 at 8 a.m. EDT to Discuss Phase 2 Clinical Trial Data for OCU410—Modifier Gene Therapy for Geographic AtrophyGlobeNewsWire • 03/23/26
OCGN Gene-Agnostic Eye Therapy Could Shift Retinal Drug DevelopmentZacks Investment Research • 03/20/26
Ocugen Provides Business Update with Fourth Quarter and Full Year 2025 Financial ResultsGlobeNewsWire • 03/04/26
Ocugen Announces Phase 3 liMeliGhT Enrollment Completion for OCU400, a Novel Modifier Gene Therapy for Broad Retinitis PigmentosaGlobeNewsWire • 03/02/26
Ocugen, Inc. Announces Closing of $22.5 Million Underwritten Registered Direct Offering of Common StockGlobeNewsWire • 01/23/26
Ocugen, Inc. (OCGN) Discusses OCU410 Phase 2 ArMaDa Trial Data and Clinical Update for Geographic Atrophy TranscriptSeeking Alpha • 01/15/26
Ocugen Announces Positive Preliminary Phase 2 Data from OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular DegenerationGlobeNewsWire • 01/15/26
Ocugen to Host Webcast on Thursday, January 15 at 8:30 a.m. ET to Discuss OCU410 Phase 2 Clinical Trial DataGlobeNewsWire • 01/13/26
Ocugen Announces Publication of Phase 1 GARDian1 Trial Results for OCU410ST Modifier Gene TherapyGlobeNewsWire • 01/12/26
Ocugen: Maintaining 'Buy' Rating On Positive OCU410ST Regulatory DevelopmentsSeeking Alpha • 01/06/26